CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid

CMS requests information from hepatitis C manufacturers on how value-based purchasing arrangements might work in Medicaid. Agency also urges state Medicaid directors to relax overly strict coverage requirements for the drugs.